Notable Labs Presents The Design Plan For PPMP-Enabled Phase 2 Trial With Volasertib For Relapsed/Refractory AML At AACR 2024
The company presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).